PMID- 15235224 OWN - NLM STAT- MEDLINE DCOM- 20040827 LR - 20190724 IS - 0031-6903 (Print) IS - 0031-6903 (Linking) VI - 124 IP - 7 DP - 2004 Jul TI - [DDS and Me]. PG - 397-415 AB - With the success of the human genome project, the focus of life science research has shifted to the functional and structural analyses of proteins, such as proteomics and structural genomics. These analyses of proteins including newly identified proteins are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic-based drug discovery and development for protein therapies, including gene therapy, cell therapy, and vaccine therapy, is attracting current attention. However, there is clinical difficulty in using almost all bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteomic-based drug discovery and development, we have attempted to develop drug delivery systems (DDSs), such as the protein-drug innovation system and the optimal cell therapeutic system. In this review, we introduce our original DDSs. FAU - Mayumi, Tadanori AU - Mayumi T AD - Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan. mayumi@pharm.kobegakuin.ac.jp LA - jpn PT - English Abstract PT - Journal Article PT - Review PL - Japan TA - Yakugaku Zasshi JT - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan JID - 0413613 RN - 0 (Vaccines) SB - IM MH - Animals MH - Cell- and Tissue-Based Therapy MH - Directed Molecular Evolution MH - *Drug Delivery Systems MH - Genetic Therapy MH - Humans MH - Nanotechnology MH - Proteomics MH - Vaccines RF - 131 EDAT- 2004/07/06 05:00 MHDA- 2004/08/28 05:00 CRDT- 2004/07/06 05:00 PHST- 2004/07/06 05:00 [pubmed] PHST- 2004/08/28 05:00 [medline] PHST- 2004/07/06 05:00 [entrez] AID - 10.1248/yakushi.124.397 [doi] PST - ppublish SO - Yakugaku Zasshi. 2004 Jul;124(7):397-415. doi: 10.1248/yakushi.124.397.